ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Bispecific antibody builder Abpro postpones $69M IPO
fiercebiotech
May 16, 2018The early-stage biotech Abpro has postponed its $69 million IPO, according to a report from Renaissance Capital, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year
Pharma Sources Insight July 2025
